BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Colombo GL, Gaeta GB, Viganò M, Di Matteo S. A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. Clinicoecon Outcomes Res 2011;3:37-46. [PMID: 21935331 DOI: 10.2147/CEOR.S16655] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Tian F, Houle SKD, Alsabbagh MW, Wong WWL. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada. Pharmacoeconomics 2020;38:181-92. [PMID: 31691902 DOI: 10.1007/s40273-019-00852-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
2 Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM. Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study. Risk Manag Healthc Policy 2020;13:43-53. [PMID: 32158289 DOI: 10.2147/RMHP.S211321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wigfield P, Sbarigia U, Hashim M, Vincken T, Heeg B. Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review. Pharmacoecon Open 2020;4:403-18. [PMID: 31428938 DOI: 10.1007/s41669-019-00175-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 La Torre G, Mannocci A, Saulle R, Colamesta V, Meggiolaro A, Mipatrini D, Sinopoli A. Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013). Hum Vaccin Immunother 2016;12:2299-311. [PMID: 27105443 DOI: 10.1080/21645515.2016.1166328] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
5 Pathak RK, Baunthiyal M, Taj G, Kumar A. Virtual screening of natural inhibitors to the predicted HBx protein structure of Hepatitis B Virus using molecular docking for identification of potential lead molecules for liver cancer. Bioinformation 2014;10:428-35. [PMID: 25187683 DOI: 10.6026/97320630010428] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
6 Buti M, Oyagüez I, Lozano V, Casado MA. Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B: a systematic review. Pharmacoeconomics. 2013;31:63-75. [PMID: 23329593 DOI: 10.1007/s40273-012-0009-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
7 Iannazzo S, De Francesco M, Coco B, Brunetto MR, Tomic R, Paolini D, Palmieri G, Bonino F. Impatto sul budget di un trattamento personalizzato dell’epatite B cronica HBeAg-negativa in Italia mediante peg-interferone alfa-2a associato alla stopping-rule alla 12a settimana. PharmacoEcon Ital Res Artic 2013;15:123-130. [DOI: 10.1007/s40276-013-0015-1] [Reference Citation Analysis]
8 Colombo GL, Di Matteo S, Antinori A, Medaglia M, Murachelli S, Rizzardini G. Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. Clinicoecon Outcomes Res 2013;5:489-96. [PMID: 24124383 DOI: 10.2147/CEOR.S48246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
9 Boccalini S, Taddei C, Ceccherini V, Bechini A, Levi M, Bartolozzi D, Bonanni P. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits. Hum Vaccin Immunother 2013;9:1119-28. [PMID: 23376840 DOI: 10.4161/hv.23827] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
10 Rizzardini G, Bonfanti P, Carenzi L, Coen M, Orlando G, Di Matteo S, Colombo GL. Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. Ther Clin Risk Manag 2012;8:377-84. [PMID: 23028230 DOI: 10.2147/TCRM.S33674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
11 Colombo GL, Di Matteo S, Bruno G. Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy. Subst Abuse Rehabil 2012;3:73-9. [PMID: 24474868 DOI: 10.2147/SAR.S30980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Vanness D, Joseph I, Marinho R, Areias J, Carvalho A, Macedo G, Matos L, Rodrigues B, Velosa J, Aragão F, Perelman J, Revankar N. Custo-utilidade do tenofovir comparado com entecavir no tratamento em primeira linha da hepatite B crónica. GE Jornal Português de Gastrenterologia 2012;19:170-182. [DOI: 10.1016/j.jpg.2012.04.008] [Reference Citation Analysis]
13 Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res 2011;3:197-205. [PMID: 22163167 DOI: 10.2147/CEOR.S24130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]